Compare SAMG & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | SERA |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.5M | 107.3M |
| IPO Year | 2012 | 2021 |
| Metric | SAMG | SERA |
|---|---|---|
| Price | $15.23 | $2.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 29.2K | 21.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.54% | N/A |
| EPS Growth | N/A | ★ 14.66 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $91,358,000.00 | $77,000.00 |
| Revenue This Year | $3.37 | $25.84 |
| Revenue Next Year | $10.62 | $715.79 |
| P/E Ratio | $27.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.23 | $1.37 |
| 52 Week High | $18.60 | $4.35 |
| Indicator | SAMG | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 33.63 |
| Support Level | $14.74 | $2.26 |
| Resistance Level | $15.41 | $3.45 |
| Average True Range (ATR) | 0.33 | 0.20 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 78.99 | 22.00 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.